Spots Global Cancer Trial Database for Phase II Two-step Radioimmunotherapy Clinical Study in Medullary Thyroid Carcinoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Phase II Two-step Radioimmunotherapy Clinical Study in Medullary Thyroid Carcinoma
Official Title: Phase II Two-step Radioimmunotherapy Clinical Study in Medullary Thyroid Carcinoma
Study ID: NCT00467506
Conditions
Interventions
Study Description
Brief Summary: Phase II clinical trial assessing efficacy and toxicity of pretargeted radioimmunotherapy using anti-CEAxanti-DTPA bispecific antibody and di-DTPA-131I peptide in patients with reccurrence of medullary thyroid carcinoma (abnormal calcitonin level and biomarkers doubling time lower than 5 years)
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Centre François Baclesse, Caen, , France
CHU de Grenoble, Grenoble, , France
hôpital du Cluzeau, Limoges, , France
CHU, Lyon, , France
Hôpital de la timone, Marseille, , France
CHU, Nantes, , France
CHU, Rouen, , France
Centre René Huguenin, Saint Cloud, , France
Centre René Gauducheau, Saint Herblain, , France
Centre Paul Strauss, Strasbourg, , France
Centre Claudius Régaud, Toulouse, , France
Contact Details
Name: Francoise Bodere, MD
Affiliation: Nantes University Hospital
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
